SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that CEO M. Scott Salka will present a company overview at the 19th Annual BIO CEO and Investor Conference on Monday, February 13, 2017 at 3:30 p.m. Eastern time (12:30 p.m. Pacific time). The conference is being held at the Waldorf Astoria New York hotel in New York City.
About BIO CEO & Investor Conference
The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. The event features plenary sessions, fireside chats, business roundtables, therapeutic workshops, company presentations and One-on-One Partnering™ meetings.
Bacteriophages, or more simply “phages,” are the natural predators of bacteria and are thought to be the most abundant life form on earth, outnumbering even the stars in our universe. Over eons, phages have evolved an incredible diversity of specialist strains that typically prey upon just one strain of bacteria, enabling a phage-based therapeutic to precisely target a pathogenic bacterial population while sparing the beneficial microbiota. Phages can infect and kill bacteria, whether they are antibiotic-resistant or not, and even when they have formed protective biofilms. Such biofilms are a major line of defense for bacteria, sometimes rendering them impervious to conventional antibiotics. Phages are able to penetrate biofilms, producing strong local therapeutic effects without the side-effects commonly produced by antibiotics.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi's product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi has reported final results from two Phase 1 clinical trials of AB-SA01, one for the treatment of Staphylococcus aureus (S. aureus) in chronic rhinosinusitis patients and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults. AmpliPhi is also developing bacteriophage therapeutics targeting Pseudomonas aeruginosa (P. aeruginosa) and Clostridium difficile (C. difficile) in collaboration with a number of leading organizations focused on the advancement of bacteriophage-based therapies. For more information, visit www.ampliphibio.com.
Media Relations (U.S.)
Danielle Lewis/Glenn Silver
Media Relations (Europe and ROW)
Gemma Howe/Sue Charles
+44 (0)20 7866 7860